About Cavion
Cavion is a Healthcare company based in Charlottesville (United States) founded in 2005, and was acquired by Jazz Pharmaceuticals in August 2019. Targeted therapies for neuropathic pain and brain cancer are developed. Cavion has raised $49.04 million across 8 funding rounds from investors including Jazz Pharmaceuticals, Lilly Ventures and Novartis Venture Fund. Its focus areas include Life Sciences, Neurology, Drugs and Diversified. Its competitors include Kriya Therapeutics, Sana Biotechnology and PureTech Health; 3 of its 3 listed competitors have raised funding.
Company details
Cavion was founded in 2005 and is based in Charlottesville, United States. Small molecule drugs for neurological disorders are developed by targeting the Cav3 molecule in T-type calcium channels. Lead candidates are advanced to phase 3 clinical trials for neuropathic pain management. Another candidate, mibefradil, is evaluated in phase II trials for recurrent glioblastoma multiforme, a form of brain cancer.
- Headquarters Charlottesville, United States
- Stage Acquired
- SectorsHealthcare
- Website cavionpharma.com
- Social LinkedIn X
- Acquired by Jazz Pharmaceuticals (Aug 2019)
- Total Equity Funding$49.04M (USD)
in 8 rounds
- Latest Funding Round$26.1M (USD), Series A
Jan 2017
- InvestorsJazz Pharmaceuticals
& 4 more
- Acquired byJazz Pharmaceuticals
(Aug 2019)
Funding Insights of Cavion
Cavion has successfully raised a total of $49.04M across 8 strategic funding rounds. The most recent funding activity was a Series A round of $26.1 million completed in January 2017. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $49.04M
- Total Rounds 8
- Last Round Series A — $26.1M
- First Round $50,000
(Jan 2007)
- Investors Count 4
All 8 funding rounds of Cavion with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan 2017 | $26.1M | Series A | – | Lilly Ventures, Novartis Venture Fund | |
| Nov 2015 | $5M | Series A | – | – | – |
| Jun 2014 | $12.84M | Series A | – | – | – |
| Jun 2012 | $200,000 | Grant | – | – | |
| Jan 2011 | $4.2M | Seed | – | – | – |
| Nov 2010 | $244,479 | Grant | – | – | – |
| Nov 2007 | $850,000 | Seed | – | – | – |
| Jan 2007 | $50,000 | Seed | – | – | – |
5 investors in total: 5 institutional.
Investors in Cavion
Cavion has secured backing from 5 investors, including venture fund and institutional investors. Prominent investors backing the company include Jazz Pharmaceuticals, Lilly Ventures and Novartis Venture Fund.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Early-stage life sciences investments are targeted in the healthcare sector. | lillyventures.com | Indianapolis, United States | ||
Investments are made in innovative life science companies globally. | nvfund.com | Basel, Switzerland | ||
| ensoventures.com | ||||
Early-stage VC firm funding companies in the US | cit.org | Herndon, United States | ||
Novel biopharmaceutical medicines are developed for unmet medical needs. | 2003 | jazzpharma.com | Dublin, Ireland |
Investor details for Cavion
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Cavion
9 people are tracked at Cavion (4 in leadership, 5 in board & advisors).
| Name | Role | Group |
|---|---|---|
Paul Sartori | VP of Operations & Strategy | Leadership |
Andrew Krouse | Founder, President, & CEO | Leadership |
Mark Versavel | Chief Medical Officer | Leadership |
Kurt Woerpel | CFO | Leadership |
Timothy MacDonald | Advisor | Board & advisors |
David E. Gibson | Director | Board & advisors |
Julia P. Gregory | Chair | Board & advisors |
Steve Hall | Director | Board & advisors |
O'Neill D'Cruz | Advisor | Board & advisors |
Complete people profiles for Cavion
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Cavion
4 dated milestones of Cavion across 14 years, from founding to its latest funding, stage changes and deals.
- Founded Cavion is founded.
- Funding First funding round of $50K.
- Funding Latest funding round, Series A, of $26.1M.
- Exit Acquired by Jazz Pharmaceuticals.
Competitors of Cavion
Cavion has 3 listed competitors in our database, 3 of them funded. They include Kriya Therapeutics, Sana Biotechnology and PureTech Health.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| kriyatherapeutics.com | 2012 | Redwood, United States | $930.93M | 159 | Developer of therapeutic solutions for the treatment of diabetes | |
| sana.com | 2018 | Seattle, United States | $821M | 328 | Genetically engineered cell therapies are developed for multiple disorders. | |
| puretechhealth.com | 2001 | Boston, United States | $107M | 171 | Immunotherapeutics are developed for inflammation, fibrosis, and lung diseases. |
Detailed competitors of Cavion
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Neurology
3 companies that operate in the same segment as Cavion (Neurology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 | |
Developer of therapeutics for psychiatric and neurologic diseases | 2002 | New York, New York, United States | USD 80.87 M | USD 250.31 M | 600 | |
Biologics platform developed for intracellular delivery in rare diseases. | 2016 | Boston, Massachusetts, United States | USD 175.25 M | USD 25.42 M | 183 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Cavion
Complete news archive for Cavion
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Cavion
Cavion was founded in 2005 and raised its 1st funding round 2 years after it was founded.
Cavion is headquartered in Charlottesville, United States. It is registered at Charlottesville, Virginia, United States.
Cavion is a funded company, having raised a total of $49.04M across 8 funding rounds to date. The company's 1st funding round was a Seed of $50K, raised on Jan 2007.
Cavion was founded in 2005 and is based in Charlottesville, United States. Small molecule drugs for neurological disorders are developed by targeting the Cav3 molecule in T-type calcium channels. Lead candidates are advanced to phase 3 clinical trials for neuropathic pain management. Another candidate, mibefradil, is evaluated in phase II trials for recurrent glioblastoma multiforme, a form of brain cancer.
Cavion's top competitors include Sana Biotechnology, PureTech Health and Kriya Therapeutics.
Cavion has 5 investors. Key investors include Jazz Pharmaceuticals, Lilly Ventures, Novartis Venture Fund, Enso Ventures, and Center for Innovative Technology.
Yes. Cavion was acquired by Jazz Pharmaceuticals in August 2019.